For this purpose, after histologic examination, NGS analysis targeting the TP53 gene (Accel-Amplicon Comprehensive TP53 panel) was performed on all samples of 77 AML-MR, MDS with increased-blast (MDS-IB), and MDS with low-blast (MDS-LB) patients. This evidence concerns the gene TP53 and acute myeloid leukemia.